1. Introduction: Peptides at the Mitochondrial Interface
The mitochondrion has long been characterised as the cell's bioenergetic hub, but research over the past two decades has reframed it as an active signalling organelle. Within this reframing, two conceptually distinct classes of peptide have attracted sustained attention in the published literature. The first comprises mitochondrial-derived peptides (MDPs) — small peptides encoded within the mitochondrial genome itself that appear to act as signalling molecules. The second comprises mitochondria-targeted peptides — synthetic sequences engineered to accumulate at the inner mitochondrial membrane and interact with its structural lipids. This review summarises the published research literature on a representative member of each class: MOTS-c, an MDP, and SS-31 (also known as elamipretide), a synthetic cardiolipin-binding tetrapeptide. The discussion is restricted to a summary of published findings and is provided for research and educational reference only.
Although the two molecules share a common organelle, they are mechanistically unrelated: MOTS-c is studied chiefly as a metabolic and transcriptional regulator, whereas SS-31 is studied for its physical association with the lipid scaffolding of mitochondrial cristae. Grouping them illustrates the breadth of contemporary mitochondrial peptide research rather than implying a shared pathway.
2. Mitochondrial-Derived Peptides: A New Class of Signalling Molecules
The discovery that the mitochondrial genome encodes functional bioactive peptides beyond the canonical thirteen oxidative-phosphorylation subunits represented a notable shift in molecular biology. Short open reading frames (sORFs) embedded within mitochondrial ribosomal RNA genes were found to encode peptides that could be detected in cells, tissues and circulation. MOTS-c — mitochondrial open reading frame of the twelve-S ribosomal RNA type-c — is among the most extensively characterised of these. The foundational report described MOTS-c as a 16-amino-acid peptide encoded by a sORF within the mitochondrial 12S rRNA region, and reported associations with systemic metabolic regulation in cell-based and rodent models (Lee et al., 2015).
The MDP concept is significant because it positions the mitochondrion as a source of retrograde signals — messages travelling outward from the organelle to influence nuclear and cellular behaviour — rather than solely a recipient of nuclear-encoded instructions. This bidirectional communication framework underpins much of the subsequent research interest in MOTS-c.
3. MOTS-c: Origin, Metabolic Signalling and AMPK
In the originating study, MOTS-c was reported to influence metabolic homeostasis in murine models, with the published data describing effects on insulin sensitivity and a reduction in the metabolic disturbances associated with a high-fat diet (Lee et al., 2015). At the molecular level, the investigators reported that MOTS-c modulates the folate-methionine cycle and engages the AMP-activated protein kinase (AMPK) pathway. AMPK is a central cellular energy sensor activated under conditions of metabolic stress, and its involvement provides a plausible biochemical framework linking the peptide to cellular energy balance in these experimental systems.
This positioning of MOTS-c upstream of, or in concert with, AMPK has made it a frequent subject of metabolic research, where it is studied alongside other energy-sensing pathways such as those involving sirtuins and NAD+ metabolism. It is important to note that these findings derive from in-vitro and rodent models and describe biochemical observations rather than validated outcomes in humans.
4. MOTS-c and Nuclear Translocation
A particularly intriguing strand of MOTS-c research concerns its subcellular movement. A subsequent study reported that, under metabolic stress, MOTS-c translocates from its mitochondrial origin to the cell nucleus, where the published data describe it associating with stress-responsive transcription factors and influencing the expression of nuclear genes in an AMPK-dependent manner (Kim et al., 2018). The authors reported that nuclear MOTS-c regulated gene sets including those bearing antioxidant response elements.
This reported behaviour is conceptually striking: a peptide encoded by the mitochondrial genome appears, in these experimental models, to act directly on nuclear transcription. Such a mechanism would represent a direct molecular conduit for mitochondrial-to-nuclear communication. As with all the work summarised here, these observations describe findings in laboratory model systems and are presented as a summary of the published research record.
5. MOTS-c and Exercise Research
The relationship between MOTS-c and physical activity has been examined in both animal and human-tissue contexts. One widely cited study reported that MOTS-c expression in skeletal muscle and circulation was responsive to exercise, and characterised the peptide as an exercise-induced, mitochondrial-encoded regulator associated with age-dependent physical decline and muscle homeostasis in mice (Reynolds et al., 2021). The published data described age-related changes in physical capacity in the rodent models studied.
This body of work has positioned MOTS-c within the broader research field of exercise mimetics and biological ageing models, where investigators study molecules that mirror aspects of the molecular response to physical activity. The findings remain confined to preclinical and tissue-level observations and should be interpreted strictly within that experimental context.
6. SS-31 (Elamipretide): Cardiolipin Binding and Cristae Architecture
SS-31 (one of the Szeto-Schiller peptides, also designated elamipretide) belongs to the entirely separate class of synthetic mitochondria-targeted peptides. Rather than being genomically encoded, it is a small aromatic-cationic tetrapeptide designed to accumulate selectively at the inner mitochondrial membrane. The defining feature reported across the literature is its high-affinity binding to cardiolipin, a phospholipid uniquely concentrated in the inner mitochondrial membrane that is required for the structural integrity of cristae — the folded membrane compartments that house the electron-transport chain (Birk et al., 2013).
Mechanistic studies reported that, by associating with cardiolipin, SS-31 influences the cytochrome c/cardiolipin complex. The published data described SS-31 limiting the conversion of cytochrome c into a peroxidase — an aberrant activity that can promote cardiolipin peroxidation — thereby preserving the electron-carrying role of cytochrome c and supporting electron transport in the experimental systems examined (Birk et al., 2014). A complementary review framed SS-31 as a cardiolipin-protective compound studied in the context of mitochondrial bioenergetics (Szeto, 2014).
7. SS-31: Preclinical and Reported Clinical Trial Context
Beyond cell-free and cell-based mechanistic work, SS-31/elamipretide has been examined in registered clinical research. A randomised dose-escalation study in adults with primary mitochondrial myopathy reported on the safety and tolerability of intravenous elamipretide and recorded exploratory functional measures within that controlled setting (Karaa et al., 2018). Separately, a randomised, placebo-controlled study examined a single infusion of elamipretide in participants with heart failure with reduced ejection fraction, again reporting principally on safety and tolerability outcomes (Daubert et al., 2017).
These studies are cited here solely to document the published research record concerning this peptide. They are summaries of investigational findings reported in the scientific literature and do not constitute, and must not be read as, any indication of efficacy, approval or suitability for any use. The molecule discussed on this site is supplied strictly as a research chemical.
8. Comparing Two Mitochondrial Mechanisms
Placing MOTS-c and SS-31 side by side highlights two divergent research philosophies. MOTS-c is an endogenous, genomically encoded signalling peptide whose published mechanism centres on metabolic regulation, AMPK engagement and reported nuclear translocation — in other words, it acts as an informational molecule that modulates cellular programmes (Lee et al., 2015) (Kim et al., 2018). SS-31, by contrast, is a synthetic structural agent whose reported mechanism is physical: it binds a specific membrane lipid and thereby influences the architecture and electron-transport function of the inner membrane (Birk et al., 2013) (Szeto, 2014).
The two therefore intersect the mitochondrion at different layers: MOTS-c at the level of signalling and gene expression, SS-31 at the level of membrane biophysics and bioenergetic flux. Neither mechanism subsumes the other, and the comparison serves to illustrate the methodological diversity of the field rather than to suggest equivalence or interchangeability.
9. Research Applications in Metabolic and Ageing Models
In the published literature, both peptides recur as tools in metabolic and biological-ageing research. MOTS-c appears in studies probing energy sensing, exercise responses and age-related physiological changes in rodent models (Reynolds et al., 2021), where it is frequently examined alongside related energy-metabolism pathways including those connected to NAD+. SS-31 features in preclinical models examining mitochondrial bioenergetics and cardiolipin biology (Birk et al., 2014), and has additionally been the subject of the registered clinical studies noted above (Karaa et al., 2018).
These applications are described here as a neutral summary of how the molecules have been used as experimental probes in the scientific record. They represent areas of active laboratory investigation and do not imply any established conclusion regarding outcomes outside those specific experimental contexts.
10. Limitations and Research-Use-Only Note
Several limitations qualify every observation summarised in this review. The majority of the mechanistic work on both MOTS-c and SS-31 derives from in-vitro systems and rodent models, and findings in such systems do not necessarily translate to other species or contexts. Where clinical research is cited, those studies were principally designed to assess safety and tolerability within tightly controlled settings, and their reported outcomes should not be generalised. Peptide stability, bioavailability, off-target activity and reproducibility across laboratories all remain active questions in the published literature.
This document is a summary of published, peer-reviewed research provided for educational and reference purposes only. It is not medical, veterinary or scientific advice, makes no health or performance claims, and describes no methods of administration. The compounds discussed are supplied strictly as research chemicals for in-vitro laboratory research use only. They are not medicinal products, are not for human or animal consumption, and are not intended to diagnose, treat, cure or prevent any condition. Readers should consult the original primary sources, cited above with their digital object identifiers, for the complete experimental detail.